Arca Ercan, Açikgöz Gürol, Taştan Halis Bülent, Köse Osman, Kurumlu Zafer
Department of Dermatology, Gülhane Military Medical Academy, School of Medicine, Etlik-Ankara, Turkey.
Dermatology. 2004;209(2):117-25. doi: 10.1159/000079595.
Androgenetic alopecia (AGA) is undoubtedly the most common form of hair loss in males. It is a condition which may cause cosmetic and psychosocial problems in androgen-dependent cases. In this open, randomized and comparative study we evaluated the efficacy of oral finasteride and 5% topical minoxidil treatment for 12 months in 65 male patients with mild to severe AGA.
We randomly assigned 40 (61.53%) patients to receive 1 mg/day oral finasteride for 12 months, and 25 (38.47%) patients applied 5% topical minoxidil solution twice daily for 12 months.
There were no significant differences between the 2 groups considering age, age of onset of hair loss, family history and type of hair loss (p > 0.05). In the clinical evaluation at the endpoint of treatment, the clinical cure rates (i.e. increased intensity of hair) were 80% (32/40) for the oral finasteride group and 52% (13/25) for the 5% topical minoxidil group. Encountered side effects were all mild, and there was no need to stop the treatment. In the group given oral finasteride, side effects were noted in 7 patients: 6 patients suffered from loss of libido, and 1 patient had an increase in other body hairs; irritation of the scalp was seen in 1 patient in the group administered 5% minoxidil. These adverse events disappeared as soon as the treatment was stopped. The laboratory data on both drug groups did not show any statistically or clinically significant intragroup changes from baseline values to the endpoint (p > 0.05), except the level of serum total testosterone which was increased, and free testosterone and serum prostate-specific antigen in the finasteride group which were statistically decreased from baseline values to the endpoint (p < 0.05).
In this comparative study of systemic finasteride and topical minoxidil, it was concluded that both drugs were effective and safe in the treatment of mild to severe AGA, although oral finasteride treatment was more effective (p < 0.05). Adverse events were not considered important either, and these side effects disappeared as soon as the treatment was stopped.
雄激素性脱发(AGA)无疑是男性最常见的脱发形式。在雄激素依赖的病例中,这种情况可能会导致美容和心理社会问题。在这项开放性、随机对照研究中,我们评估了口服非那雄胺和5%外用米诺地尔治疗65例轻至重度AGA男性患者12个月的疗效。
我们随机分配40例(61.53%)患者接受每日1mg口服非那雄胺治疗12个月,25例(38.47%)患者每日两次外用5%米诺地尔溶液治疗12个月。
两组在年龄、脱发起始年龄、家族史和脱发类型方面无显著差异(p>0.05)。在治疗终点的临床评估中,口服非那雄胺组的临床治愈率(即头发密度增加)为80%(32/40),5%外用米诺地尔组为52%(13/25)。出现的副作用均较轻微,无需停止治疗。口服非那雄胺组有7例出现副作用:6例性欲减退,1例身体其他部位毛发增多;外用5%米诺地尔组有1例出现头皮刺激。这些不良事件在治疗停止后立即消失。除血清总睾酮水平升高,非那雄胺组游离睾酮和血清前列腺特异性抗原从基线值到终点有统计学意义的下降(p<0.05)外,两组药物的实验室数据从基线值到终点均未显示出任何统计学或临床显著的组内变化(p>0.05)。
在这项系统性非那雄胺与外用米诺地尔的对比研究中,得出结论:两种药物在治疗轻至重度AGA方面均有效且安全,尽管口服非那雄胺治疗效果更佳(p<0.05)。不良事件也不被认为严重,且这些副作用在治疗停止后立即消失。